

11 December 2025

NON-HODGKIN'S LYMPHOMA (NHL), CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) AND ACUTE MYELOID LEUKAEMIA (AML)

Q1. How many patients were treated in total, regardless of diagnosis, with the following medicines in the

3 months between the start of July 2025 and end of September 2025, or latest 3-month period available?

Name of medicine	Number patients treated
1.1 Acalabrutinib (Calquence)	
1.2 Ibrutinib (Imbruvica)	
1.3 Pirtobrutinib (Jaypirca)	
1.4 Venetoclax (Venclyxto)	
1.5 Zanubrutinib (Brukinsa)	
1.6 Rituximab	
1.7 Obinutuzumab (Gazyvaro)	

*Belfast Trust does not hold this information centrally as electronic prescribing is not in place for haematology. To retrieve it would require a manual trawl of individual patient records, which would take more than 18 hours.

*We estimate that compliance with this (element of the) request for information would exceed the appropriate costs limit. Under Section 12 of the Freedom of Information 2000.